DexCom Inc (DXCM)vsIntelligent Bio Solutions Inc. (INBS)
DXCM
DexCom Inc
$73.74
+1.94%
HEALTHCARE · Cap: $28.45B
INBS
Intelligent Bio Solutions Inc.
$2.44
-3.94%
HEALTHCARE · Cap: $6.77M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 123016% more annual revenue ($4.82B vs $3.91M). DXCM leads profitability with a 19.3% profit margin vs -296.8%. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
INBS
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$669.08
Current Price
$73.74
$595.34 discount
Margin of Safety
-23.2%
Fair Value
$4.26
Current Price
$2.44
$1.82 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while INBS is a hypergrowth play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.24 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 38/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?